Tag: ErbB2

Trastuzumab-based therapeutics: Choosing the appropriate species for safety studies

Written by
Dr Gail Lewis Phillips researches trastuzumab based therapies and argues that rodents are not the best choice for safety studies as the equivalent antigen (neu) does not bind

Trastuzumab is a clinically approved monoclonal antibody therapy which targets HER2 (or ErbB2) for treatment of HER2-overexpressing breast and gastric cancers. Safety studies are important in the development of antibody therapeutics and should use animal species which bind the target antigen (HER2) to understand target-mediated effects, in addition to a non-binding species to observe non-targeted effects. It is acknowledged that […]

Read More… from Trastuzumab-based therapeutics: Choosing the appropriate species for safety studies